122734-32-1

Basic information

• Product Name: tert-Butyl 2-(methylamino)ethylcarbamate
• Synonyms: 1-BOC-AMINO-2-METHYLAMINO-ETHANE;BUTTPARK 90\06-21;TERT-BUTYL 2-(METHYLAMINO)ETHYLCARBAMATE;Boc-2-(Methylamino)ethylcarbamate;Carbamic acid, [2-(methylamino)ethyl]-, 1,1-dimethylethyl ester (9CI);N-(tert-Butoxycarbonyl)-N-methylethylenediamine;tert-Butyl 2-(methylamino)ethylcarbamate HCl;1-BOC-Amino-2-methylamino-ethane(HClform)
• CAS NO: 122734-32-1
• Molecular Formula: C₈H₁₈N₂O₂
• Molecular Weight: 174.24
• Product Categories: N-BOC
• Mol File: 122734-32-1.mol

Chemical Properties

• Melting Point: 35 °C
• Boiling Point: 260.1 °C at 760 mmHg
• Flash Point: 111.1 °C
• Appearance: /
• Density: 0.958 g/cm³
• Vapor Pressure: 0.0125mmHg at 25°C
• Refractive Index: 1.441
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 12?+-.0.46(Predicted)
• CAS DataBase Reference: tert-Butyl 2-(methylamino)ethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 2-(methylamino)ethylcarbamate(122734-32-1)
• EPA Substance Registry System: tert-Butyl 2-(methylamino)ethylcarbamate(122734-32-1)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 122734-32-1(Hazardous Substances Data)

Usage

Chemical Properties

White to very pale yellow solid

InChI:InChI=1/C8H18N2O2/c1-8(2,3)12-7(11)10-6-5-9-4/h9H,5-6H2,1-4H3,(H,10,11)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 109-81-9 N-methyl-ethane-1,2-diamine 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 57260-73-8 N-BOC-1,2-diaminoethane 
• 74-88-4 methyl iodide 
• 71999-74-1 tert-butyl N-(2-chloroethyl)carbamate 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 74-89-5 methylamine 
• 849472-99-7 [2-(benzylmethylamino)ethyl]carbamic acid tert-butyl ester 
• 174799-52-1 tert-butyl {2-[benzylamino]ethyl}carbamate 
• 1432971-80-6 C₁₆H₂₄N₂O₄ 
• 214000-16-5 N-(tert-butoxycarbonyl)-N'-(2-nitrobenzenesulfonyl)ethylenediamine 
• 49761-82-2 tert-butyl 1H-imidazole-1-carboxylate 

Downstream Products

• 909804-24-6 (2-{[(2-tert-butoxycarbonylamino-ethyl)-methyl-amino]-methyl}-phenyl)-boronic acid 
• 328084-02-2 (2-{[1-(3,4-Dichloro-benzyl)-piperidin-4-yl]-methyl-amino}-ethyl)-carbamic acid tert-butyl ester 
• 1149367-42-9 C₂₁H₂₇N₃O₄ 
• 1204318-22-8 tert-butyl 2-(2-hydroxy-N-methylbenzamido)ethylcarbamate 

Relevant articles and documents

Microwave-assisted synthesis and biological evaluation of novel uracil derivatives inhibiting human thymidine phosphorylase

New 5-chloro-6-substituted-uracil derivatives have been prepared by microwave assisted-synthesis and tested in vitro as thymidine phosphorylase inhibitors. One of these compounds showed potent inhibitory activity, with an IC50 value in the subm

Preparation method of (2-methylamine-ethyl)-tert-butyl carbamate

The invention discloses a preparation method of (2-methylamine-ethyl)-tert-butyl carbamate, and belongs to the technical field of organic chemical synthesis. The preparation method comprises followingsteps: 1, imidazole is dissolved in dichloromethane, and di-tert-butyl dicarbonate ester is added at room temperature, reaction is carried out for 2 to 3h at room temperature, and water washing drying are carried out so as to obtain an intermediate; and 2, the intermediate is dissolved in toluene, N-methylethylenediamine is added, an obtained mixture is heated to 60 to 70 DEG C, reaction is carried out for 2 to 4h, reduced pressure distillation is carried out to remove toluene, and purification is carried out so as to obtain (2-methylamine-ethyl)-tert-butyl carbamate. The operation steps arefew; by-product content is reduced with ensured (2-methylamine-ethyl)-tert-butyl carbamate synthesis yield; cost is relatively low; and batch production requirements are satisfied.

Design and synthesis of novel PRMT1 inhibitors and investigation of their binding preferences using molecular modelling

Protein arginine methyltransferase 1 (PRMT1) catalyses the methylation of substrate arginine by transferring the methyl group from SAM (S-adenosyl-L-methionine), which leads to the formation of S-adenosyl homocysteine (SAH) and methylated arginine. We have shown previously that the Asp84 on PRMT1 could be a potential inhibitor binding site. In the current study, 28 compounds were designed and synthesized that were predicted to bind the Asp84 and substrate arginine sites together. Among them, 6 compounds were identified as potential PRMT1 inhibitors, and showed strong inhibitory effects on cancer cell lines, especially HepG2. The most potent PRMT1 inhibitor, compound 13d, was selected for molecular dynamic simulations to investigate binding poses. Based on the free energy calculations and structural analysis, we predicted that the ethylenediamine group would tightly bind to Asp84, and the trifluoromethyl group should occupy part of substrate arginine binding site, which is consistent with our original goal. Our results show for the first time that PRMT1 inhibitors can target the Asp84 binding site, which will be helpful for future drug discovery studies.

An enzyme and its optional [...] modified ketone and inhibitor composition comprising (by machine translation)

PROBLEM TO BE SOLVED: ketone-containing acrylic misuse, abuse or overload is prevented for a new takable amt. provitamin drag pain. SOLUTION: a compound represented by the following formula is represented, in which the drag oxystyrene provitamin hydrocodone ketone-containing acrylic. Pre-selected drug profile is modified and the ketone and schisandrin [...] holding hung contg. compsn. method for administration to a patient. Selected drawing: no (by machine translation)

MACROCYCLIC ACTIVIN-LIKE RECEPTOR KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of Activin-like receptor kinases, more in particular ALK1 and/or ALK2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of ALK1-kinase and/or ALK2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

IMMUNOMODULATORY CONJUGATES

The present invention provides an immunomodulatory compound comprising a carbohydrate polymer comprising mannose, wherein the carbohydrate polymer is conjugated to at least one immune modulator. The present invention also provides for the use of this compound in immunomodulatory compositions for vaccination and gene therapy methods, together with processes for its preparation.

COMPOUNDS AND METHODS

Disclosed are compounds having formula I, wherein X1, X2, X3, R1, R2, R3, R4, R5, Y, A, Z, L, m and n are as defined herein, and methods of making and using the same.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF

The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF

The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.